Researchers
Discover a New Way the Body Fights Yeast Infection
School of Medicine study in 'Cell, Host and Microbe' uncovers how
cells search for and destroy Candida albicans, a common yeast infection
A team
of researchers led by Amy G. Hise, M.D., M.P.H., assistant professor
at the Center for Global Health and Diseases, Case Western Reserve
University School of Medicine, is the first to discover how the
body fights off oral yeast infections caused by the most common
human fungal pathogen, Candida.
As
fungal infections become more resistant to current drugs, this groundbreaking
research may directly lead to the development of new drugs and therapies
that will help limit and/or prevent Candida infections in the future
for millions of sufferers.
Candida
albicans is the most common species of the Candida fungus and is
the leading cause of vaginal and oral yeast infections, including
thrush and denture stomatitis. It is the fourth most common hospital
acquired bloodborne pathogen in the United States and surprisingly,
it is present in the mouths of 30 to 50 percent of healthy adults.
Because
of the widespread nature of Candida, the potential for overgrowth
and infection is common in the young, elderly, immuno-compromised
and people receiving corticosteroid or chemotherapy treatments.
The
findings, published in Cell, Host and Microbe, identified the critical
role of a protein, interleukin-1? or IL-1?, secreted by a variety
of cells in the human immune system to protect the body from oral
colonization by Candida albicans and preventing it from spreading
to infect host tissue and blood. The study defines the precise mechanism
by which the body's immune cells produce IL-1? following contact
with Candida albicans. Further, it shows that a complex of proteins,
collectively termed the NLRP3 inflammasome, function to produce
IL-1? from an inactive, precursor form into a form that can be secreted
by cells and subsequently function to modulate the immune system
and its responses.
This
research clarifies a number of mechanisms and pathways that may
be therapeutic targets to help alleviate and/or eliminate Candida
overgrowth and its accompanying symptoms, such as pain and discomfort,
swelling, burning sensation of affected area, difficulty swallowing,
in individuals suffering from infections.
The
findings of Dr. Hise's laboratory will open many new avenues of
research in fungal infections. One direction they are pursuing is
to identify the way that the fungus activates the inflammasome.
This might provide new targets for drug development. Another area
of interest is the investigation of how small differences between
individuals in immune related genes, called single nucleotide polymorphisms
or SNPs, affect susceptibility to fungal and other infections.
"If
we can identify patterns of SNPs that make people more likely to
develop life-threatening fungal infections, it may be possible in
the future to use these as markers to screen patients. For example,
patients admitted to intensive care units or needing long-term invasive
catheters could be genetically screened to identify who would benefit
from preventive anti-fungal treatment," says Dr. Hise.
Disclaimer:
Throughout this website, statements are made pertaining to the properties and/or
functions of food and/or nutritional products. These statements have not been
evaluated by the Food and Drug Administration and these materials and products
are not intended to diagnose, treat, cure or prevent any disease.